Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib

Recent efforts to personalize treatment with platinum-based chemotherapy and PARP inhibitors have produced promising results in homologous recombinant deficient (HRD) metastatic pancreatic cancer (MPC). However, new strategies are necessary to overcome resistance. The below case series documents pat...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Gehan Botrus, Denise Roe, Gayle S. Jameson, Pedro Luiz Serrano Uson Junior, Ronald Lee Korn, Lana Caldwell, Taylor Bargenquast, Max Miller, Erkut Hasan Borazanci
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2022-10-01
Schriftenreihe:	Biomedicines
Schlagworte:	pancreatic cancer BRCA Olaparib homologous recombination deficient mitomycin
Online-Zugang:	https://www.mdpi.com/2227-9059/10/11/2705
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!